Given that EGFR-mutated lung cancer was previously shown in a study based on NGS to have a lower mutation burden compared with lung cancer wild-type for EGFR [27], it may be difficult to identify concurrent actionable driver mutations in patients with EGFR or HER2 mutations. This evidence concerns the gene EGFR and lung cancer.